Commercial payers are spending almost twice as much on chemotherapy administered in hospital outpatient departments compared with therapy administered in physician offices.
A study to be presented at the BMT Tandem Meetings found no difference in OS for patients aged 55-64 years compared with those aged 65 years and older with non-Hodgkin lymphoma who underwent alloHCT.
FDA-approved CAR T-cell therapies may be associated with high costs, but the therapies are priced in alignment with their clinical value, according to an Institute for Clinical and Economic Review evidence report.
Health care providers and patients have identified a need for further resources to support survivorship care in gynecologic oncology, according to a presentation given at the 2018 ASCO Cancer Survivorship Symposium.
A recent study evaluated health care utilization and costs of pulmonary arterial hypertension in a real-world setting by comparing periods before and after treatment initiation.
A systematic review presented at the 2018 ASCO Cancer Survivorship Symposium determined whether survivorship care plans have a positive impact on health outcomes and health care delivery.
A National Cancer Database analysis revealed racial and ethnic disparities in patients with gastric cancer in the use of preoperative chemotherapy and in outcomes.
A recent study found that a biosimilar provides improved outcomes without increased risk of toxicity for patients with DLBCL and treatment-induced neutropenia.
A study presented at the ASCO Cancer Survivorship Symposium evaluated the impact of a breast cancer survivorship model on health system resources and costs.
Survival outcomes may be worse for patients with ALL living in intermediate and high socioeconomically deprived areas as well as for those treated in hospitals with lower volumes of patients.